Use of chimeric antigen receptor modified cells to treat cancer
AssigneeInnovative Cellular Therapeutics Holdings, Ltd.
InventorsLei Xiao, Chengfei Pu, Zhiyuan Cao, He Sun, Mao Bi, Zhao Wu
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to compositions and methods for compositions, methods, and kits for treating cancer using chimeric antigen receptor (CAR) modified cells. Some embodiments of the present disclosure relate to an isolated nucleic acid sequence encoding CAR. The CAR may include an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. The antigen binding domain may bind to an antigen of a non-essential organ.
Claims9
A method of stimulating a T cell-mediated immune response and treating colorectal cancer in a human patient, the method comprising:
- contacting a population of cells comprising guanylate cyclase 2C (GUCY2C) comprising the amino acid sequence of SEQ ID NO:
- 33, in a human patient with a population of modified T cells comprising a chimeric antigen receptor (CAR),
- and stimulating a T cell-mediated immune response and treating colorectal cancer in a human patient,
- wherein the CAR comprises an extracellular domain, a transmembrane domain, and an intracellular domain, the extracellular domain comprising the amino acid sequences SEQ ID NO:
- 14.
Dependencies are inferred from the claim text.